HOME >> BIOLOGY >> NEWS
Vitamin E in plant seeds could halt prostate, lung cancer, says Purdue scientist

WEST LAFAYETTE, Ind. - The form of vitamin E found in many plant seeds - but not in most manufactured nutritional supplements - might halt the growth of prostate and lung cancer cells, according to a Purdue University study.

A team led by Qing Jiang (pronounced "ching zhang") has found that gamma-tocopherol, which occurs naturally in walnuts, pecans, sesame seeds, and in corn and sesame oils, inhibits the proliferation of lab-cultured human prostate and lung cancer cells. The vitamin's presence interrupts the synthesis of certain fatty molecules called sphingolipids, important components of cell membranes. However, the gamma-tocopherol leaves healthy human prostate cells unaffected, which could give it value as an anticancer agent.

"This is the first time gamma-tocopherol has been shown to induce death in lab-grown human cancer cells while leaving healthy cells alone," said Jiang, who is an assistant professor of foods and nutrition in the College of Consumer and Family Sciences. "This could be wonderful news for cancer patients if the effect can be reproduced in animal models. But because most nutritional supplements contain only alpha-tocopherol, a different form of vitamin E that alone does not have these anticancer properties, it may be better to supplement the diet with mixed forms of vitamin E. The study shows that the anticancer effect is enhanced when mixed forms are used."

Jiang's research appears in the current (week of Dec. 13) online edition of the scientific journal Proceedings of the National Academy of Sciences. She co-authored the paper with Jeffrey Wong, Henrik Fyrst, Julie D. Saba and Bruce N. Ames of the Children's Hospital Oakland Research Institute in Oakland, Calif.

Scientists have been studying vitamin E for more than three-quarters of a century, but most efforts have focused largely on alpha-tocopherol, one of eight known forms in the vitamin's family. Alpha-tocopherol was found early on to have the mo
'"/>

Contact: Chad Boutin
cboutin@purdue.edu
765-494-2081
Purdue University
14-Dec-2004


Page: 1 2 3

Related biology news :

1. Vitamin extends life in yeast, Dartmouth Medical School researchers find
2. Vitamin D, variations in its receptor and prostate cancer
3. Vitamin D deficiency widespread during pregnancy
4. Vitamin D3 provides the skin with protection from harmful microbes
5. Vitamin C and water not just healthy for people -- healthy for plastics, too
6. Vitamin D may cut pancreatic cancer risk by nearly half
7. Vitamin D and flavonoids examined for impact on breast and ovarian cancers
8. Nutritional friend or foe? Vitamin E sends mixed messages
9. Vitamin A analog is a potential lung cancer preventative with few side effects
10. Vitamin supplement could help treatment-resistant asthma
11. Vitamin As paradoxical role in influencing symmetry during embryonic development revealed

Post Your Comments:
(Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: